Research programme: antifibrotics - Nitto Denko/Quark Pharmaceuticals
Latest Information Update: 04 Nov 2017
At a glance
- Originator Nitto Denko; Quark Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Small interfering RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Fibrosis in Japan (Parenteral)
- 12 Jun 2013 Early research is ongoing Japan
- 15 Jul 2010 Early research in Fibrosis in Japan (Parenteral)